Daiichi Sankyo Emerges as a Rising Global Oncology Leader with Flagship ADC Enhertu

Jun 27, 2026 14:00 CST Updated 14:00

Daiichi - Sankyo

Pharmaceutical Development, Production, Sales, and Consulting Service Provider

AstraZeneca

Pharmaceutical Technology Research and Development Provider

Johnson & Johnson

Medical Device R&D and Manufacturer

With its blockbuster drug, trastuzumab deruxtecan, theDaiichi Sankyo has established its position in antibody-drug conjugates（ADC）leading position in the field. In 2025, global sales of trastuzumab deruxtecan reached $5 billion, representing a year-on-year increase of 32.71%. Analysts predict that future sales of this product could even surpass $15 billion.

However, Daiichi Sankyo is not content with this. Recently, it has announced a new slogan: by 2035, toBecome a Top 5 Global Oncology Pharmaceutical Company。

Yet, none of those standing on this battlefield are ordinary opponents.Merck & Co. has Keytruda, BMS has Opdivo and an extensive oncology immunotherapy portfolio, Roche has long been deeply engaged in breast cancer, lung cancer, and hematologic malignancies, AstraZeneca is rapidly expanding with osimertinib, durvalumab, and a series of ADCs, while Johnson & Johnson continues to increase its investment in multiple myeloma. In other words, the top five positions in the global oncology market are basically occupied byWith blockbuster products, a global commercial network, and a robust R&D systemoccupied by MNCs.

So, how did Daiichi Sankyo, which has only just begun to make its mark on the global market, manage to break in? In today’s video, we’ll break down the trump cards that Daiichi Sankyo holds.

Editor: Yueya

Cover Source:Corporate logo / Zcool Hailuo

Disclaimer:This article is for informational purposes only and does not represent the stance or views of Insight, nor does it constitute recommendations or introductions to treatment plans. If needed, please consult and contact legitimate medical institutions.